Clinical Research, Pharma & Healthcare FinancingXolair Shows Greater Efficacy, Fewer Side Effects than OITBusiness WireMarch 3, 2025March 4, 2025 by Business WireMarch 3, 2025March 4, 2025016 First-ever head-to-head trial comparing Xolair and oral immunotherapy (OIT) Results were featured as late-breakers at the 2025 AAAAI Annual Meeting Xolair is the only U.S....
